Literature DB >> 16782056

Inactivation of TGF-beta signaling in lung cancer results in increased CDK4 activity that can be rescued by ELF.

Hye Jung Baek1, Sang Soo Kim, Fabio May da Silva, Eugene A Volpe, Stephen Evans, Bibhuti Mishra, Lopa Mishra, M Blair Marshall.   

Abstract

Escape from TGF-beta inhibition of proliferation is a hallmark of multiple cancers including lung cancer. We explored the role of ELF, crucial TGF-beta adaptor protein identified from endodermal progenitor cells, in lung carcinogenesis and cell-cycle regulation. Interestingly, elf-/- mice develop multiple defects that include lung, liver, and cardiac abnormalities. Four out of 6 lung cancer and mesothelioma cell lines displayed deficiency of ELF expression with increased CDK4 expression. Immunohistochemistry and Western blot analysis of primary human lung cancers also showed decreased ELF expression and overexpression of CDK4. Moreover, rescue of ELF in ELF-deficient cell lines decreased the expression of CDK4 and resulted in accumulation of G1/S checkpoint arrested cells. These results suggest that disruption in TGF-beta signaling mediated by loss of ELF in lung cancer leads to cell-cycle deregulation by modulating CDK4 and ELF highlights a key role of TGF-beta adaptor protein in suppressing early lung cancer.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16782056     DOI: 10.1016/j.bbrc.2006.05.195

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  10 in total

1.  Crosstalk of AP4 and TGFβ receptor signaling in NSCLC.

Authors:  Wei Wang; Xinyu Wu; Yu Tian
Journal:  Tumour Biol       Date:  2014-10-01

2.  Transforming growth factor-β adaptor, β2-spectrin, modulates cyclin dependent kinase 4 to reduce development of hepatocellular cancer.

Authors:  Hye Jung Baek; Michael J Pishvaian; Yi Tang; Tae Hyun Kim; Shaoxian Yang; Majed El Zouhairi; Jon Mendelson; Kirti Shetty; Bhaskar Kallakury; Deborah L Berry; Kyung Hwan Shin; Bibhuti Mishra; E Premkumar Reddy; Sang Soo Kim; Lopa Mishra
Journal:  Hepatology       Date:  2011-05       Impact factor: 17.425

3.  Hepatocellular cancer arises from loss of transforming growth factor beta signaling adaptor protein embryonic liver fodrin through abnormal angiogenesis.

Authors:  Hye Jung Baek; Sung Chul Lim; Krit Kitisin; Wilma Jogunoori; Yi Tang; M Blair Marshall; Bibhuti Mishra; Tae Hyun Kim; Kwan Ho Cho; Sang Soo Kim; Lopa Mishra
Journal:  Hepatology       Date:  2008-10       Impact factor: 17.425

4.  βII-Spectrin (SPTBN1) suppresses progression of hepatocellular carcinoma and Wnt signaling by regulation of Wnt inhibitor kallistatin.

Authors:  Xiuling Zhi; Ling Lin; Shaoxian Yang; Krithika Bhuvaneshwar; Hongkun Wang; Yuriy Gusev; Mi-Hye Lee; Bhaskar Kallakury; Narayan Shivapurkar; Katherine Cahn; Xuefei Tian; John L Marshall; Stephen W Byers; Aiwu R He
Journal:  Hepatology       Date:  2015-02       Impact factor: 17.425

Review 5.  Spectrin-based skeleton as an actor in cell signaling.

Authors:  B Machnicka; R Grochowalska; D M Bogusławska; A F Sikorski; M C Lecomte
Journal:  Cell Mol Life Sci       Date:  2011-08-30       Impact factor: 9.261

6.  The prognostic value of combined TGF-β1 and ELF in hepatocellular carcinoma.

Authors:  Fei Ji; Shun-Jun Fu; Shun-Li Shen; Long-Juan Zhang; Qing-Hua Cao; Shao-Qiang Li; Bao-Gang Peng; Li-Jian Liang; Yun-Peng Hua
Journal:  BMC Cancer       Date:  2015-03-11       Impact factor: 4.430

7.  Mathematical modeling of Interleukin-35 promoting tumor growth and angiogenesis.

Authors:  Kang-Ling Liao; Xue-Feng Bai; Avner Friedman
Journal:  PLoS One       Date:  2014-10-30       Impact factor: 3.240

8.  SPTBN1 inhibits inflammatory responses and hepatocarcinogenesis via the stabilization of SOCS1 and downregulation of p65 in hepatocellular carcinoma.

Authors:  Ling Lin; Shuyi Chen; Hua Wang; Bin Gao; Bhaskar Kallakury; Krithika Bhuvaneshwar; Katherine Cahn; Yuriy Gusev; Xue Wang; Yunan Wu; John L Marshall; Xiuling Zhi; Aiwu Ruth He
Journal:  Theranostics       Date:  2021-02-20       Impact factor: 11.556

9.  SPTBN1 suppresses the progression of epithelial ovarian cancer via SOCS3-mediated blockade of the JAK/STAT3 signaling pathway.

Authors:  Mo Chen; Jia Zeng; Shuyi Chen; Jiajia Li; Huijie Wu; Xuhui Dong; Yuan Lei; Xiuling Zhi; Liangqing Yao
Journal:  Aging (Albany NY)       Date:  2020-06-08       Impact factor: 5.682

Review 10.  βII spectrin (SPTBN1): biological function and clinical potential in cancer and other diseases.

Authors:  Panyu Yang; Yanyan Yang; Pin Sun; Yu Tian; Fang Gao; Chen Wang; Tingyu Zong; Min Li; Ying Zhang; Tao Yu; Zhirong Jiang
Journal:  Int J Biol Sci       Date:  2021-01-01       Impact factor: 6.580

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.